NO900646L - Fremgangsmaate for fremstilling av calsiumantagonister. - Google Patents

Fremgangsmaate for fremstilling av calsiumantagonister.

Info

Publication number
NO900646L
NO900646L NO90900646A NO900646A NO900646L NO 900646 L NO900646 L NO 900646L NO 90900646 A NO90900646 A NO 90900646A NO 900646 A NO900646 A NO 900646A NO 900646 L NO900646 L NO 900646L
Authority
NO
Norway
Prior art keywords
represented
alkyl
group
substituent
calcium antagonists
Prior art date
Application number
NO90900646A
Other languages
English (en)
Norwegian (no)
Other versions
NO900646D0 (no
Inventor
Albert Anthony Carr
John Michael Kane
Hsien Chang Cheng
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/457,997 external-priority patent/US5106845A/en
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO900646D0 publication Critical patent/NO900646D0/no
Publication of NO900646L publication Critical patent/NO900646L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Amplifiers (AREA)
  • Details Of Resistors (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
NO90900646A 1989-02-10 1990-02-09 Fremgangsmaate for fremstilling av calsiumantagonister. NO900646L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30975089A 1989-02-10 1989-02-10
US07/457,997 US5106845A (en) 1990-01-10 1990-01-10 Calcium antagonists

Publications (2)

Publication Number Publication Date
NO900646D0 NO900646D0 (no) 1990-02-09
NO900646L true NO900646L (no) 1990-08-13

Family

ID=26976983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90900646A NO900646L (no) 1989-02-10 1990-02-09 Fremgangsmaate for fremstilling av calsiumantagonister.

Country Status (14)

Country Link
EP (1) EP0389765B1 (fi)
JP (1) JP2879918B2 (fi)
KR (1) KR0149165B1 (fi)
CN (1) CN1044813A (fi)
AT (1) ATE110367T1 (fi)
AU (1) AU621193B2 (fi)
CA (1) CA2009542C (fi)
DE (1) DE69011714T2 (fi)
ES (1) ES2063177T3 (fi)
FI (1) FI900650A0 (fi)
HU (1) HU204795B (fi)
NO (1) NO900646L (fi)
NZ (1) NZ232396A (fi)
PT (1) PT93106A (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW245719B (fi) * 1990-09-10 1995-04-21 Sterling Winthrop Inc
US5380721A (en) * 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
US5314903A (en) * 1991-12-03 1994-05-24 Neurosearch A/S Benzimidazole compounds useful as calcium channel blockers
CA2104060A1 (en) * 1992-11-10 1994-05-11 Robert Ed Johnson Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136188A (en) * 1976-06-25 1979-01-23 Daiichi Seiyaku Co., Ltd. Treatment of diabetes with 2-substituted-1,3-diazacyclic compounds
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4174401A (en) * 1977-07-13 1979-11-13 Mcneil Laboratories, Incorporated 2-Benzhydrylimino-imidazolidines
US4243667A (en) * 1979-01-30 1981-01-06 Mcneil Laboratories, Incorporated 2-Benzhydrylimino-1,3-diazacarbocyclic compounds as inhibitors of gastric secretion
US4235894A (en) * 1979-01-30 1980-11-25 Mcneilab, Inc. 2-Benzhydrylimino-1,3-diazacarbocyclic compounds, compositions and methods of use
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
FR2658823B1 (fr) * 1990-02-27 1992-04-30 Adir Nouveaux derives d'aminomethylpiperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent .

Also Published As

Publication number Publication date
HUT53089A (en) 1990-09-28
NO900646D0 (no) 1990-02-09
CA2009542C (en) 2000-03-14
KR900012918A (ko) 1990-09-03
ES2063177T3 (es) 1995-01-01
HU204795B (en) 1992-02-28
EP0389765A1 (en) 1990-10-03
DE69011714T2 (de) 1994-12-15
PT93106A (pt) 1990-08-31
AU4932590A (en) 1990-08-16
KR0149165B1 (ko) 1998-10-15
HU900728D0 (en) 1990-04-28
JP2879918B2 (ja) 1999-04-05
EP0389765B1 (en) 1994-08-24
NZ232396A (en) 1991-07-26
AU621193B2 (en) 1992-03-05
CA2009542A1 (en) 1990-08-10
DE69011714D1 (de) 1994-09-29
CN1044813A (zh) 1990-08-22
FI900650A0 (fi) 1990-02-09
JPH02282368A (ja) 1990-11-19
ATE110367T1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
DK160877C (da) Fremgangsmaade til fremstilling af 2-penemforbindelser
ATE169008T1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
ATE380818T1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
IL66650A (en) Dibenzoxepines and dibenzooxazepines,their preparation and pharmaceutical compositions containing them
KR950704294A (ko) 축합 벤조화합물(fused benzo compounds)
ATE117295T1 (de) 4-oxochinolin-3-carbonsäure-derivate, ihre herstellung und ihre verwendung.
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
DE3777852D1 (de) Dekahydrochinolinderivate, verfahren zu ihrer herstellung, zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende zubereitungen.
ATE137220T1 (de) Benzen-, pyridin-, pyrimidinderivat
ES2111930T3 (es) Antagonistas del acido amp y procedimientos de tratamiento con la ayuda de estos.
NO890440L (no) Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
ES2052181T3 (es) Derivados de 2-oxo-1-oxa-8-azaespiro(4,5)decano, procesos para su preparacion y composiciones farmaceuticas de los mismos.
NO900646D0 (no) Fremgangsmaate for fremstilling av calsiumantagonister.
ES2099180T3 (es) Derivados del benzopirano y procedimientos para su preparacion.
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
MX9204457A (es) Compuestos de 6-oxo-azepinoidol, asi como procedimientos y productos intermedios para su preparacion, y medicamentos que contienen estos compuestos.
DE69402703D1 (de) 3-(INDOL-3-YL) PROPENSäURDERIVATE, DIE ALS NMDA- ANTAGONISTEN NÜTZLICH SIND
EA199900460A1 (ru) Производные бензолсульфоамида и лекарственные средства, содержащие упомянутые производные
KR900011769A (ko) 신규 벤조[1,8] 나프티리딘 유도체 및 그의 제법
ES2082273T3 (es) Nuevos derivados del benzopirano y procesos para su preparacion.
ATE56442T1 (de) 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES497949A0 (es) Procedimiento para la preparacion de nuevos 4-amino-2,6-dia-riltetrahidrotiopiranos sustituidos
ATE99306T1 (de) Antagonisten von leukotrien d4.
JO1047B1 (en) Vehicles